{"id":"W2755607580","doi":"10.1016/s0140-6736(17)32365-6","title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Docetaxel; Ramucirumab; Medicine; Internal medicine; Placebo; Metastatic Urothelial Carcinoma; Hazard ratio; Clinical endpoint; Oncology; Population; Tolerability; Discontinuation; Chemotherapy; Surgery; Clinical trial; Adverse effect; Cancer; Confidence interval; Bladder cancer; Urothelial carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001914431,0.001894571,0.003812972,0.0004608338,0.0004233275,0.001302871,0.001127759,0.001803957,0.00650992],"category_scores_gemma":[0.001881975,0.0008592514,0.002820933,0.0004384199,0.001249604,0.001399765,0.0004566473,0.003761949,0.00130195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008031823,"about_ca_system_score_gemma":0.0007922673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107828,"about_ca_topic_score_gemma":0.002360516,"domain_scores_codex":[0.9992411,0.0004179588,0.00004191805,0.0001535006,0.0000369396,0.0001086438],"domain_scores_gemma":[0.9992853,0.0002510305,0.0001587168,0.00006150525,0.00003719217,0.000206383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9824048,0.00207022,0.0002151964,0.0006997944,0.0007988511,0.00002782588,0.00004886481,0.0002826519,0.001171918,0.00007670972,0.0005684046,0.01163488],"study_design_scores_gemma":[0.9569774,0.04080436,0.0008107621,0.00003587344,0.0004266189,0.00002601097,0.00001620586,0.0002320812,0.000157012,0.0001176336,0.0003805975,0.00001555994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9732372,0.01578459,0.0007964922,0.001129927,0.001265931,0.002988047,0.001172668,0.0003193222,0.003305868],"genre_scores_gemma":[0.9847599,0.00480241,0.001328341,0.001148214,0.0005810063,0.002063173,0.000794391,0.00003952233,0.004483087],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00650992,"threshold_uncertainty_score":0.02177787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07605140914426525,"score_gpt":0.350020755068268,"score_spread":0.2739693459240027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}